Diagnosed six years ago, now beating the then published life expectancy of 5-7 years of a rare incurable form of blood cancer, a lymphoplasmacytic lymphoma called Waldenstrom's Macroglobulinemia (WM), Jack Whelan is determined to help in the research, care and ultimate cure of this rare cancer which affects about 1200 new patients each year. Jack is betting on Clinical Trials.
WM has many similarities with Multiple Myeloma and non-Hodgkins Lymphoma; many of the chemotherapies, immunotherapies and other emerging B cell malignancy targeting treatments including biologic agents are used to battle this unique, uncommon blood cancer.
As Waldenstroms is an orphan blood cancer, it doesn't get much attention and no government-specific funding for research and the quest for a cure. However, there is a small but effective group of patients, caregivers, physicians, researchers and other medical and pharmaceutical professionals who through the efforts of the International Waldenstrom's Macroglobulinemia Foundation (IWMF) lead the charge in research and care of patients and caregivers living with this cancer.
Active volunteer/advocate with the Leukemia, Lymphoma Society, (LLS) supporter of Team in Training, Light the Night, currently supporting LLS, American Cancer Society (ACS) DFCI and others educating Massachusetts state legislators to get support for oral chemotherapy parity regulations, a move that will save all parties significant healthcare costs while providing pharmacy coverage (for pill-form chemotherapy) at the same rate for patients that would normally be covered when receiving chemotherapy in the infusion room.
Jack was recently featured on the cover of Cancer Today.
See more at: <a href="http://www.jack-whelan.com/whos_jack" title="www.jack-whelan.com">http://www.jack-whelan.com/whos_jack</a>
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register